Krystal Biotech, Inc. (KRYS)
341.78
-4.80
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
341.78
0.00 (0.00%)
After-Hours: 19:57
Krystal Biotech Total Assets (Quarterly) : 1.501B for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.501B |
| March 31, 2026 | 1.397B |
| December 31, 2025 | 1.334B |
| September 30, 2025 | 1.240B |
| June 30, 2025 | 1.138B |
| March 31, 2025 | 1.074B |
| December 31, 2024 | 1.056B |
| September 30, 2024 | 982.32M |
| June 30, 2024 | 917.66M |
| March 31, 2024 | 853.30M |
| December 31, 2023 | 818.36M |
| September 30, 2023 | 790.35M |
| June 30, 2023 | 684.03M |
| March 31, 2023 | 531.85M |
| December 31, 2022 | 558.45M |
| September 30, 2022 | 576.38M |
| June 30, 2022 | 601.32M |
| March 31, 2022 | 616.87M |
| December 31, 2021 | 626.30M |
| September 30, 2021 | 451.10M |
| Date | Value |
|---|---|
| June 30, 2021 | 443.56M |
| March 31, 2021 | 443.02M |
| December 31, 2020 | 310.84M |
| September 30, 2020 | 311.45M |
| June 30, 2020 | 318.14M |
| March 31, 2020 | 205.13M |
| December 31, 2019 | 209.02M |
| September 30, 2019 | 214.23M |
| June 30, 2019 | 205.16M |
| March 31, 2019 | 115.70M |
| December 31, 2018 | 116.12M |
| September 30, 2018 | 54.45M |
| June 30, 2018 | 46.03M |
| March 31, 2018 | 47.85M |
| December 31, 2017 | 50.11M |
| September 30, 2017 | 52.67M |
| June 30, 2017 | 3.977M |
| March 31, 2017 | 2.151M |
| December 31, 2016 | 2.182M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 14.59M |
| TG Therapeutics, Inc. | 1.640B |
| Tenaya Therapeutics, Inc. | 93.54M |
| Cytokinetics, Inc. | 1.925B |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 141.52M |
| Shareholders Equity (Quarterly) | 1.359B |
| Debt to Equity Ratio | 0.0065 |
| Current Ratio | 8.318 |
| Net Debt Paydown Yield | 0.00% |